First Header Logo Second Header Logo

Connection

Steven Park to Lymphoma, Non-Hodgkin

Back to Details
This is a "connection" page, showing publications Steven Park has written about Lymphoma, Non-Hodgkin.
Steven Park
Connection Strength
1.386
Lymphoma, Non-Hodgkin
  1. Au KM, Wang AZ, Park SI. Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma. Sci Adv. 2020 Apr; 6(14):eaaz9798.
    View in: PubMed
    Score: 0.705
  2. Park SI, Lin CP, Ren N, Angus SP, Dittmer DP, Foote M, Parton T, Bhatt AP, Fedoriw YD, Roth DP, Cann ML, Johnson GL, Damania B. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma. Target Oncol. 2019 Oct; 14(5):563-575.
    View in: PubMed
    Score: 0.681
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.